Canaan’s Tim Shannon argues in BioCentury that solution for hi price of orphans is to lower marketing, development costs via innovative disintermediation. Disagree: cost of making/selling drugs largely unrelated to price. https://t.co/qpU45e9FoP
ABBV’s new-ish elagolix hardly a payer favorite – so why does Myovant think payers will react differently to relugolix? Biopharma R&D/investors need more objective understanding of value-to-payers.
@RegeneronLen intriguing & brave infrastructure financing idea – all public co’s issue additional 1% equity to https://t.co/XgI8CxXFnB US infrastructure "bank" – might also hint at way to fund patient cost-shares etc. for hi-cost drugs.
People in MedAdantage cost less than trad Medicare? Not because of better MedAdvantage management, study says. https://t.co/dIiggJL0TL My bet: more affluent people in MedAd – and richer folks healthier (because they can afford to take care better care?) & thus cost system less.
@peterbachmd Yup. Question I had was whether costs could come down dramatically -- e.g., if significantly clearer/surer approval path + sure way of getting paid for it so could finance the project. But article is great -- and shows need for alternatives (with biologics & elsewhere).
Fascinating proposal 10.1377/HBLOG20190405.396631 by @peterbachmd https://t.co/Xn4B4siKW3. on price controls for post-patent biologicals. Alternative: pre-agreed biosim price from payer, without PA…enabling MD-directed substitution.
ESI excluding Lilly’s half-price Humalog in favor of rebated drug (& often higher cost share for diabetics) mostly about rebate guarantees to its clients. More troublesome structural incentives. https://t.co/p68Cr0zvbF
@DShaywitz Depends on what you mean by "regulatory". Govt has gone backwards when it comes to value-based medicine, certainly equally important to public health & patient finances as tech advances and faster drug approvals.